antineoplaston a10
Small moleculeexperimental
Clinical trial activity
46 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
46
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 1993 (NCT00003535)
Timeline
1990s
- Jan 1, 1993
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
- Adenocarcinoma · Phase 2
- Adrenocortical Carcinoma · Phase 2
- Astrocytoma · Phase 2
- Breast Neoplasms · Phase 2
- Carcinoma · Phase 2
- Carcinoma, Islet Cell · Phase 2
- Carcinoma, Merkel Cell · Phase 2
- Carcinoma, Neuroendocrine · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Colonic Neoplasms · Phase 2
- Esophageal Neoplasms · Phase 2
- Glioblastoma · Phase 2
- Glioma · Phase 2
- Head and Neck Neoplasms · Phase 2
- Intestinal Neoplasms · Phase 2
- Kidney Neoplasms · Phase 2
- Liver Neoplasms · Phase 2
- Lung Neoplasms · Phase 2
- Lymphoma · Phase 2
- Lymphoma, Mantle-Cell · Phase 2
- Lymphoma, Non-Hodgkin · Phase 2
- Melanoma · Phase 2
- Mesothelioma, Malignant · Phase 2
- Multiple Myeloma · Phase 2
- Neoplasms · Phase 2
- Neuroblastoma · Phase 2
- Neuroectodermal Tumors, Primitive · Phase 2
- Oligodendroglioma · Phase 2
- Ovarian Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 2
- Pituitary Neoplasms · Phase 2
- Prostatic Neoplasms · Phase 2
- Sarcoma · Phase 2
- Small Cell Lung Carcinoma · Phase 2
- Stomach Neoplasms · Phase 2
- Urinary Bladder Neoplasms · Phase 2
- Uterine Cervical Neoplasms · Phase 2
- Vulvar Neoplasms · Phase 2
- Waldenstrom Macroglobulinemia · Phase 2
Mechanism of action
- Flavin reductaseBINDING AGENT
BLVRB binding agent
Chemistry & pharmacology
Loading structure…
SMILES
O=C1CC[C@H](NC(=O)Cc2ccccc2)C(=O)N1- Mol. weight
- 246.27 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1980825 ↗
Also known as
- antineoplaston a10
- antineoplaston a10
- antineoplaston a10
- antineoplaston a 10
- antineoplaston a 10
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00003486 | Phase 2 | Nov 1, 1999 | Burzynski Research Institute |
| NCT00003502 | Phase 2 | Nov 1, 1999 | Burzynski Research Institute |
| NCT00003536 | Phase 2 | Nov 1, 1999 | Burzynski Research Institute |
| NCT00003514 | Phase 2 | Nov 1, 1999 | Burzynski Research Institute |
| NCT00003455 | Phase 2 | Nov 1, 1999 | Burzynski Research Institute |
| NCT00003505 | Phase 2 | Nov 1, 1999 | Burzynski Research Institute |
| NCT00003517 | Phase 2 | Nov 1, 1999 | Burzynski Research Institute |
| NCT00003456 | Phase 2 | Nov 1, 1998 | Burzynski Research Institute |
| NCT00003501 | Phase 2 | Aug 1, 1998 | Burzynski Research Institute |
| NCT00003489 | Phase 2 | Aug 1, 1998 | Burzynski Research Institute |
| NCT00003471 | Phase 2 | Aug 1, 1998 | Burzynski Research Institute |
| NCT00003491 | Phase 2 | Aug 1, 1998 | Burzynski Research Institute |
| NCT00003454 | Phase 2 | Aug 1, 1998 | Burzynski Research Institute |
| NCT00003494 | Phase 2 | Aug 1, 1998 | Burzynski Research Institute |
| NCT00003512 | Phase 2 | Aug 1, 1998 | Burzynski Research Institute |
| NCT00003500 | Phase 2 | Aug 1, 1998 | Burzynski Research Institute |
| NCT00003485 | Phase 2 | Aug 1, 1998 | Burzynski Research Institute |
| NCT00003497 | Phase 2 | Aug 1, 1998 | Burzynski Research Institute |
| NCT00003496 | Phase 2 | Aug 1, 1998 | Burzynski Research Institute |
| NCT00003495 | Phase 2 | Aug 1, 1998 | Burzynski Research Institute |
Showing 20 of 46 trials
Page 1 / 3
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Burzynski Research Institute | Academic/Hospital | 46 | 46 | 1 | 1993 |
1 organizations
Page 1 / 1